Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147

被引：0
|
作者：
Foster, Paul G. [1 ]
机构：
[1] Exelixis Inc, San Francisco, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3592S / 3592S
页数：1
相关论文
共 50 条
  • [1] Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor
    Shapiro, Geoffrey I.
    Edelman, Gerald
    Calvo, Emiliano
    Aggarwal, Sanjay K.
    Laird, A. Douglas
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3594S - 3594S
  • [2] Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors
    Shapiro, G.
    Kwak, E.
    Baselga, J.
    Rodon, J.
    Scheffold, C.
    Laird, A. D.
    Bedell, C.
    Edelman, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
    Foster, Paul
    Yamaguchi, Kyoko
    Hsu, Pin P.
    Qian, Fawn
    Du, Xiangnan
    Wu, Jianming
    Won, Kwang-Ai
    Yu, Peiwen
    Jaeger, Christopher T.
    Zhang, Wentao
    Marlowe, Charles K.
    Keast, Paul
    Abulafia, Wendy
    Chen, Jason
    Young, Jenny
    Plonowski, Artur
    Yakes, F. Michael
    Chu, Felix
    Engell, Kelly
    Bentzien, Frauke
    Lam, Sanh T.
    Dale, Stephanie
    Yturralde, Olivia
    Matthews, David J.
    Lamb, Peter
    Laird, A. Douglas
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (04) : 931 - 940
  • [4] Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
    Matulonis, Ursula
    Vergote, Ignace
    Backes, Floor
    Martin, Lainie P.
    McMeekin, Scott
    Birrer, Michael
    Campana, Frank
    Xu, Yi
    Egile, Coumaran
    Ghamande, Sharad
    GYNECOLOGIC ONCOLOGY, 2015, 136 (02) : 246 - 253
  • [5] Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models
    Gravina, Giovanni Luca
    Mancini, Andrea
    Scarsella, Luca
    Colapietro, Alessandro
    Jitariuc, Ana
    Vitale, Flora
    Marampon, Francesco
    Ricevuto, Enrico
    Festuccia, Claudio
    TUMOR BIOLOGY, 2016, 37 (01) : 341 - 351
  • [6] PI3 kinase targeting agents: XL147 and XL765
    DeCillis, A.
    Baselga, J.
    Edelman, G.
    LoRusso, P.
    Markman, B.
    Papadopoulous, K.
    Shapiro, G.
    Aggarwal, S.
    Nguyen, L.
    Laird, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 21 - 21
  • [7] A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies
    Edelman, G.
    Bedell, C.
    Shapiro, G.
    Pandya, S. S.
    Kwak, E. L.
    Scheffold, C.
    Nguyen, L. T.
    Laird, A.
    Baselga, J.
    Rodon, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors
    Faulkner, Neil
    LoRusso, Patricia M.
    Guthrie, Tina
    Soria, Jean-Charles
    Bahleda, Ratislav
    Bendell, Johanna C.
    Infante, Jeffrey R.
    Massard, Christophe
    Van Leeuwen, Barbara
    Martini, Jean-Francois
    Scheffold, Christian
    Burns, Howard A.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [9] A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors
    Calvo, E.
    Edelman, G.
    Baselga, J.
    Kwak, E.
    Scheffold, C.
    Nguyen, L.
    Shapiro, G. I.
    EJC SUPPLEMENTS, 2008, 6 (12): : 69 - 69
  • [10] Evaluation of peripheral blood cells and hair as surrogate tissues for clinical trial pharmacodynamic assessment of XL147 and XL765, inhibitors of the PI3K signaling pathway
    Laird, A. D.
    Sillman, A.
    Sun, B.
    Mengistab, A.
    Chu, F.
    Lee, M.
    Cancilla, B.
    Aggarwal, S. K.
    Bentzien, F.
    EJC SUPPLEMENTS, 2008, 6 (12): : 30 - 30
12345